This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

Claim 1 (original): A pharmaceutical composition comprising a liposome associated with at least one polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof.

Claim 2 (original): A pharmaceutical composition according to claim 1, wherein said composition comprises a liposome associated with at least one polypeptide comprising SEQ ID No : 2.

Claim 3 (original): A pharmaceutical composition according to claim 1, wherein said composition comprises a liposome associated with at least one polypeptide consisting of SEQ ID No : 2 or a fragment or analog thereof.

Claim 4 (original): A pharmaceutical composition according to claim 1, wherein said composition comprises a liposome associated with at least one polypeptide consisting of SEQ ID No : 2.

Claim 5 (original): A pharmaceutical composition comprising a liposome associated with at least one epitope bearing portion of a polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof.

Claim 6 (original): A pharmaceutical composition according to claim 5, wherein said composition comprises a liposome associated with at least one epitope bearing portion of a polypeptide comprising SEQ ID No : 2.

Claim 7 (original): A pharmaceutical composition comprising a liposome associated with at least one isolated polypeptide, wherein said isolated polypeptide is selected from:

DOCKET NO. PHARMA-330

(a)   a polypeptide having at least 70% identity to a second polypeptide comprising SEQ ID No : 2 or fragment or analog thereof;

(b)   a polypeptide having at least 80% identity to a second polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof;

(c)   a polypeptide having at least 95% identity to a second polypeptide comprising SEQ ID No : 2 or a fragments ·or analog thereof;

(d)   a polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof;

(e)   a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof;

(f)   an epitope bearing portion of a polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof;

(g)   the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted; and

(h)   the polypeptide of (a), (b), (c), (d), (e), (f) or (g) wherein the secretory amino acid sequence is deleted.

Claim 8 (original): A pharmaceutical composition according to claim 7, wherein said isolated polypeptide is selected from:

(a)   a polypeptide having at least 70% identity to a second polypeptide comprising SEQ ID No : 2;

(b)   a polypeptide having at least 80% identity to a second polypeptide comprising SEQ ID No : 2;

(c)   a polypeptide having at least 95% identity to a second polypeptide comprising SEQ ID No : 2;

(d)   a polypeptide comprising SEQ ID No : 2;

(e)   a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising SEQ ID No : 2;

(f)   an epitope bearing portion of a polypeptide comprising SEQ ID No : 2;

(g)   the polypeptide of (a), (b), (c), (d), (e) or (f) wherein the N-terminal Met residue is deleted;

DOCKET NO. PHARMA-330

and

(h)   the polypeptide of (a), (b), (c), (d), (e), (f) or (g) wherein the secretory amino acid sequence is deleted.

Claim 9 (original): A pharmaceutical composition comprising a liposome associated with at least one isolated polynucleotide, wherein said isolated polynucleotide is selected from:

(a)   a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof;

(b)   a polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof;

(c)   a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof;

(d)   a polynucleotide encoding a polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof;

(e)   a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof;

(f)   a polynucleotide encoding an epitope bearing portion of a polypeptide comprising SEQ ID No : 2 or a fragment or analog thereof;

(g)   a polynucleotide comprising SEQ ID No : 1 or a fragment or analog thereof; and

(h)   a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g).

Claim 10 (original): A pharmaceutical composition according to claim 9, wherein said isolated polynucleotide is selected from:

(a)   a polynucleotide encoding a polypeptide having at least 70% identity to a second polypeptide comprising SEQ ID No : 2;

(b)   a polynucleotide encoding a polypeptide having at least 80% identity to a second polypeptide comprising SEQ ID No : 2;

(c)   a polynucleotide encoding a polypeptide having at least 95% identity to a second polypeptide comprising SEQ ID No : 2;

DOCKET NO. PHARMA-330

(d)   a polynucleotide encoding a polypeptide comprising SEQ ID No : 2;

(e)   a polynucleotide encoding a polypeptide capable of raising antibodies having binding specificity for a polypeptide comprising SEQ ID No : 2;

(f)   a polynucleotide encoding an epitope bearing portion of a polypeptide comprising SEQ ID No : 2;

(g)   a polynucleotide comprising SEQ ID No : 1 or fragments or analogs thereof; and

(h)   a polynucleotide that is complementary to a polynucleotide in (a), (b), (c), (d), (e), (f) or (g).

Claim 11 (original):   A pharmaceutical comprising a liposome associated with chimeric polypeptides comprising two or more polypeptides comprising SEQ ID No : 2 or a fragment or analog thereof, wherein said polypeptides are linked as to formed a chimeric polypeptide.

Claim 12 (original): A pharmaceutical composition according to claim 10, wherein said composition comprises a liposome associated with chimeric polypeptides comprising two or more polypeptides comprising SEQ ID No : 2 wherein said polypeptides are linked as to form a chimeric polypeptide.

Claim 13 (currently amended):   A pharmaceutical composition according to ~~any one of claims 1 to 12~~ claim 1, wherein said liposome comprises lipids selected from synthetic phospholipids, bacterial phospholipids and/or cholesterol.

Claim 14 (original):   A pharmaceutical composition according to claim 13, wherein said liposome comprises bacterial lipids extracted from E. coli, N. meningitidis, or N. lactamica.

Claim 15 (currently amended):   A pharmaceutical composition according to ~~any one of claims 1 to 12~~ claim 1, wherein said liposome comprises lipids selected from phosphatidyl ethers and esters, glycerides, gangliosides, sphyngomyelin, and steroids.

Claim 16 (original): A pharmaceutical composition according to claim 13, wherein said lipids are selected from:

1,2-Dilauroyl-*sn*-Glycero-3-Phosphate (DLPA),

Dimyristoyl-*sn*-Glycero-3-Phosphate (DMPA),

1,2-Dipalmitoyl-*sn*-Glycero-3-Phosphate (DPPA),

1,2-Distearoyl-*sn*-Glycero-3-Phosphate (DSPA),

1,2-Dioleoyl-*sn*-Glycero-3-Phosphate (DOPA),

1-Palmitoyl-2-Oleoyl-*sn*-Glycero-3-Phosphate (POPA),

1,2-Dilauroyl-*sn*-Glycero-3-Phosphocholine (DLPC),

1,2-Ditridecanoyl-*sn*-Glycero-3-Phosphocholine,

1,2-Dimyristoyl-*sn*-Glycero-3-Phosphocholine (DMPC),

1,2-Dipentadecanoyl-*sn*-Glycero-3-Phosphocholine,

1,2-Dipalmitoyl-*sn*-Glycero-3-Phosphocholine (DPPC),

1,2-Diheptadecanoyl-*sn*-Glycero-3-Phosphocholine,

1,2-Distearoyl-*sn*-Glycero-3-Phosphocholine (DSPC),

1,2-Dimyristoleoyl-*sn*-Glycero-3-Phosphocholine,

1,2-Dipalmitoleoyl-*sn*-Glycero-3-Phosphocholine,

1,2-Dioleoyl-*sn*-Glycero-3-Phosphocholine (DOPC),

1-Myristoyl-2-Palmitoyl-*sn*-Glycero-3-Phosphocholine,

1-Myristoyl-2-Stearoyl-*sn*-Glycero-3-Phosphocholine,

1-Palmitoyl-2-Myristoyl-*sn*-Glycero-3-Phosphocholine,

1-Palmitoyl-2-Stearoyl-*sn*-Glycero-3-Phosphocholine,

1-Palmitoyl-2-Oleoyl-*sn*-Glycero-3-Phosphocholine (POPC),

1-Palmitoyl-2-Linoleoyl-*sn*-Glycero-3-Phosphocholine,

1,2-Dilauroyl-*sn*-Glycero-3-Phosphoethanolamine (DLPE),

1,2-Dimyristoyl-*sn*-Glycero-3-Phosphoethanolamine (DMPE),

1,2-Dipalmitoyl-*sn*-Glycero-3-Phosphoethanolamine (DPPE),

1,2-Dipalmitoleoyl-*sn*-Glycero-3-Phosphoethanolamine,

1,2-Distearoyl-*sn*-Glycero-3-Phosphoethanolamine (DSPE),

DOCKET NO. PHARMA-330

1,2-Dioleoyl-*sn*-Glycero-3-Phosphoethanolamine (DOPE),

1-Palmitoyl-2-Oleoyl-*sn*-Glycero-3-Phosphoethanolamine (POPE),

1,2-Dilauroyl-*sn*-Glycero-3-[Phospho-*RAC*-(1-glycerol)] (DLPG),

1,2-Dimyristoyl-*sn*-Glycero-3-[Phospho-*RAC*-(1-glycerol)] (DMPG), 1,2-Dipalmitoyl-*sn*-
Glycero-3-[Phospho-*RAC*-(1-glycerol)] (DPPG), 1,2-Distearoyl-*sn*-Glycero-3-[Phospho-*RAC*-(1-
glycerol)] (DSPG),

1,2-Dioleoyl-*sn*-Glycero-3-[Phospho-*RAC*-(1-glycerol)] (DOPG),

1-Palmitoyl-2-Oleoyl-*sn*-Glycero-3-[Phospho-*RAC*-(1-glycerol)] (POPG),

1,2-Dilauroyl-*sn*-Glycero-3-[Phospho-L-Serine] (DLPS),

1,2-Dimyristoyl-*sn*-Glycero-3-[Phospho-L-Serine] (DMPS),

1,2-Dipalmitoyl-*sn*-Glycero-3-[Phospho-L-Serine] (DPPS),

1,2-Distearoyl-*sn*-Glycero-3-[Phospho-L-Serine] (DSPS),

1,2-Dioleoyl-*sn*-Glycero-3-[Phospho-L-Serine] (DOPS), and

1-Palmitoyl-2-Oleoyl-*sn*-Glycero-3-[Phospho-L-Serine] (POPS).

Claim 17 (original):   A pharmaceutical composition according to claim 13, wherein said liposome further comprises at least oned adjuvant selected from Lipid A, monophosphoryl lipid A (MPLA), lipopolysaccharides, and cytokines.

Claim 18 (original):   A pharmaceutical composition according to claim 13, wherein said liposome comprises 0 to 25% cholesterol.

Claim 19 (currently amended):   A pharmaceutical composition according to ~~any one of claims 1 to 18~~ claim 1, wherein said composition further comprises a pharmaceutically acceptable adjuvant.

Claim 20 (currently amended):   A method for inducing an immune response against N. meningitidis, in a host, comprising administering to said host an immunogenically effective amount of a pharmaceutical composition according to ~~any of claims 1 to 19~~ claim 1 to elicit an immune

response.

Claim 21 (currently amended): A method for preventing and/or treating a <u>N. meningitidis</u> infection comprising administering to a host in need thereof a prophylactic or therapeutic amount of a pharmaceutical composition according to ~~any of claims 1 to 19~~ <u>claim 1</u>.

Claim 22 (currently amended): A method for preventing and/or treating a neisserial infection selected from <u>N. meningitidis</u>, <u>N. gonorrhoeae</u>, <u>N. lactamica</u> and <u>N. polysaccharea</u> comprising administering to a host in need thereof a prophylactic or therapeutic amount of a pharmaceutical composition according ~~to any of claims 1 to 19~~ <u>claim 1</u>.

Claim 23 (currently amended): A method for the treatment or prophylaxis of meningitidis and meningoccemia, in a host, comprising administering to said host an effective amount of a pharmaceutical composition according to ~~any of claims 1 to 19~~ <u>claim 1</u>.

Claim 24 (currently amended): A method according to ~~any one of claims 20 to 23~~ <u>claim 20</u>, wherein said host is a mammal.

Claim 25 (original): A method according to claim 24, wherein said host is a human.

Claim 26 (original): A method according to claim 25, wherein said host is an adult human.

Claim 27 (currently amended): A method according to ~~any one of claims 20 to 26~~ <u>claim 20</u> wherein said are administered in unit dosage form of about 0.001 to 100 μg/kg (antigen/body weight) with an interval of about 1 to 6 week intervals between immunizations.

Claim 28 (currently amended): A diagnostic method for detecting <u>N. meningitidis</u> organism in a biological sample, comprising:
  a)   obtaining a biological sample from a host;

b)   incubating an antibody or fragment thereof reactive with a pharmaceutical composition according to ~~any one of claims 1 to 19~~ claim 1 with the biological sample to form a mixture; and

c)   detecting specifically bound antibody or bound fragment in the mixture which indicates the presence of N. meningitidis.

Claim 29 (currently amended): A diagnostic method for detecting N. meningitidis organism in a biological sample, comprising:

a)   obtaining a biological sample from a host;

b)   incubating a pharmaceutical composition according to ~~any one of claims 1 to 19~~ claim 1 with the biological sample to form a mixture; and

c)   detecting specifically bound antigen or bound fragment in the mixture which indicates the presence of antibody specific to N. meningitidis.

Claim 30 (original): A diagnostic method for detecting N. meningitidis organism in a biological sample, comprising:

a)   obtaining the biological sample from a host;

b)   incubating one or more DNA probes having a DNA sequence encoding a polypeptide comprising SEQ ID No : 2 or a fragment thereof with the biological sample to form a mixture; and

c)   detecting specifically bound DNA probe in the mixture which indicates the presence of N. meningitidis bacteria.

Claim 31 (currently amended): A diagnostic method for detecting N. meningitidis in a host comprising:

a)   labelling an antibody reactive with a pharmaceutical composition according to ~~any one of claims 1 to 19~~ claim 1 with a detectable label;

b)   administering the labelled antibody to the host; and

c)   detecting specifically bound labelled antibody or labelled fragment in the host which indicates the presence of <u>N. meningitidis</u>.

Claim 32 (currently amended): Use of a pharmaceutical method according to ~~any one of claims 1 to 19~~ <u>claim 1</u> for the prophylactic or therapeutic treatment of <u>N. meningitidis</u> infection in an individual susceptible to <u>N. meningitidis</u> infection comprising administering to said individual a therapeutic or prophylactic amount of said.

Claim 33 (currently amended): A kit comprising a according to ~~any one of claims 1 to 19~~ <u>claim 1</u> for detection of diagnosis of <u>N. meningitidis</u> infection.

         DOCKET NO. PHARMA-330